


Amendments to the Claims:

This Listing of Claims will replace all prior versions and listings of claims in the application.

Listing Of Claims

- 1.(currently amended) A method of treating mammary carcinoma, wherein the method comprises administering a therapeutically effective amount of an alkylphosphocholine compound of the general Formula II:



Formula II

in which, independently of one another,

n, m, p, z is a whole number between 0 and 4;

x is O, S, NH;


R is hydrogen, a linear or branched C₁ to C₂₀ alkyl group, which may be saturated or unsaturated with one to three double and/or triple bonds and unsubstituted or optionally substituted at the same or at different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, C₁ to C₆ alkoxy, amino, mono-(C₁ to C₄) alkylamino or di-(C₁ to C₄) alkylamino groups;

R₁, R₂ independently of one another represent hydrogen, a linear or branched (C₁ to C₆) alkyl group, preferably methyl and ethyl, a (C₃-C₇)-cycloalkyl group, which may be unsubstituted or optionally substituted at the same or different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, C₁ to C₆ alkoxy, amino, mono-(C₁ to C₄) alkylamino or di-(C₁ to C₄) alkylamino groups and pharmaceutically acceptable salts thereof; wherein said alkylphosphocholine is administered before and/or during treatment with an

antimetabolite approved antitumor substance chosen from carboplatinum,
oxaliplatinum, bleomycin, methotrexate, paclitaxel, docetaxel, vineristine,
vinblastine, etoposide, teniposide, ifosfamide, 5-fluorouracil, fludarabin,
gemcitabin and cytarabin.

2. (canceled)

3. (currently amended) A method of treating mammary carcinoma, wherein said method
comprises administering a therapeutically effective amount of an alkylphosphocholine
compound of the general Formula II:



Formula II

where, independently of one another,

m, p are the integer 1;

n, z are the integer 2;

x is O;

R is H or a straight-chain or branched (C₁-C₁₇)-alkyl group which may be saturated
or unsaturated with one to three double and/or triple bonds;

R₁, R₂ are, independently of one another, H or a straight-chain or branched (C₁-
C₆)-alkyl group, preferably methyl and ethyl, a (C₃-C₇)-cycloalkyl group;

wherein said alkylphosphocholine is administered before and/or during treatment
with an antimetabolite approved antitumor substance chosen from
carboplatinum, oxaliplatinum, bleomycin, methotrexate, paclitaxel, docetaxel,
vineristine, vinblastine, etoposide, teniposide, ifosfamide, 5-fluorouracil,
fludarabin, gemcitabin and cytarabin.

4. (currently amended) A method of treating mammary carcinoma, wherein said method comprises administering a therapeutically effective amount of octadecyl 1,1-dimethylpiperidinium-4-yl phosphate (perifosine) ~~as claimed in claim 1 wherein said alkylphosphocholine is administered~~ before and/or during treatment with an antimetabolite approved antitumor substance chosen from ~~carboplatinum, oxaliplatinum, bleomycin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.~~

Claim 5. (canceled)

Claim 6. (canceled)

Claim 7. (canceled)

Claim 8 (canceled)

Claim 9 (canceled)

Claim 10 (canceled)

Claim 11 (canceled)

Claim 12. (currently amended) A drug product consisting essentially of an alkylphosphocholine of the general Formula II as in claims 1, 3, or 4 and, where appropriate, carriers and/or excipients for use in the treatment of mammary carcinoma wherein the drug product is administered before and/or during the treatment with an approved antitumor substance chosen from ~~carboplatinum, oxaliplatinum, bleomycin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.~~

Claim 13 (canceled)